跳至主要内容
临床试验/TCTR20230603003
TCTR20230603003尚未招募4 期

Comparison of the effectiveness of Acapella and BreatheMAX devices on secretion clearance and quality of life in patients with non-cystic fibrosis Bronchiectasis randomized crossover trial.

Science Promotion Fund Research and Innovation (SCF Fund) : Fundamental Fund Type Fund for the fiscal year 20230 个研究点目标入组 24 人开始时间: 2023年6月3日最近更新:
适应症

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 85 Years(—)
性别
All

入选标准

  • Age is 18-85 years,
  • -Confirmed diagnosis of bronchiectasis with or without other respiratory disease (eg, COPD) by physician (X-rays, CT chest)
  • -reported daily sputum production (>10 ml) or crackles or rhonchi during listening of lung's auscultation and rhonchal fremitus.
  • -Good cooperation and able to follow the command
  • -Stable vital signs (temperature, heart rate, blood pressure, respiratory rate)

排除标准

  • - cystic fibrosis
  • -SpO2 < 90%
  • -Active pulmonary tuberculosis
  • -Exacerbation within 1 months
  • -Any cancer
  • -Cardiac dysfunction & hemodynamic instability
  • -History of brain aneurism or retinal detachment, recent facial, oral, or skull surgery, abdominal aneurism
  • -Neurological: old CVD and SCI
  • -Pregnancy

研究者

发起方
Science Promotion Fund Research and Innovation (SCF Fund) : Fundamental Fund Type Fund for the fiscal year 2023

相似试验